<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
	<channel>
	<link>http://salesandmarketingnetwork.com/hsmn_newsfeed_public.rss</link>
	<title>HSMN NewsFeed</title>
	<description><![CDATA[Healthcare Sales & Marketing Network NewsFeed]]></description>
	<lastBuildDate>Fri, 03 Feb 2012 19:53:17 CST</lastBuildDate>
	<language>en-us</language>
	<image>
	<title><![CDATA[The Healthcare Sales & Marketing Network]]></title>
	<width>150</width>
	<height>67</height>
	<link>http://salesandmarketingnetwork.com/news.php</link>
	<url>http://salesandmarketingnetwork.com/images/hsmn_logo_150.gif</url>
	</image>
	<item>
		 <title><![CDATA[Prometheus Announces New Chief Commercial Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034461</link>
			<pubDate>Fri, 03 Feb 2012 13:25:33 GMT</pubDate>
			<author><![CDATA[Prometheus Laboratories]]></author>
		 <description><![CDATA[SAN DIEGO, Feb. 3, 2012  (HSMN NewsFeed)  -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the appointment of Anthony J. Yost as Senior Vice President and Chief Commercial Officer.

Tony joins Prometheus... <br/><font color="red">Diagnostics, Personnel</font><br/><font color="blue">Prometheus Laboratories</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034460</link>
			<pubDate>Fri, 03 Feb 2012 12:45:03 GMT</pubDate>
			<author><![CDATA[Threshold Pharmaceuticals]]></author>
		 <description><![CDATA[* Threshold to receive $25 million upfront, plus further potential milestones and royalties

* Deal provides Threshold option to co-commercialize in the United States

* Phase 3 trial in soft tissue sarcoma on-going and randomized Phase II trial in pat... <br/><font color="red">Biopharmaceuticals, Oncology</font><br/><font color="blue">Threshold Pharmaceuticals, Merck KGaA, TH-302, soft tissue sarcoma</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Caris Diagnostics Announces Name Change to Miraca Life Sciences]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034459</link>
			<pubDate>Fri, 03 Feb 2012 12:39:31 GMT</pubDate>
			<author><![CDATA[Miraca Life Sciences]]></author>
		 <description><![CDATA[Company to Provide Same High-Quality Anatomic Pathology Services Under New Name

TOKYO and IRVING, Texas, Feb. 3, 2012 --(HSMN NewsFeed) -- Caris Diagnostics, specializing in academic-caliber anatomic pathology services, today announced a company name ch... <br/><font color="red">Diagnostics</font><br/><font color="blue">Miraca Life Sciences, Caris Diagnostics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Ronnie Andrews Joins Life Technologies as President, Medical Sciences]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034458</link>
			<pubDate>Thu, 02 Feb 2012 13:14:54 GMT</pubDate>
			<author><![CDATA[Life Technologies]]></author>
		 <description><![CDATA[Leveraging 25-Plus Years Diagnostic Industry Experience, Andrews Will Shape Life Technologies Molecular Diagnostics Business

CARLSBAD, Calif., Feb. 2, 2012  (HSMN NewsFeed)  -- Life Technologies Corporation (NASDAQ: LIFE ) today announced that Ronnie An... <br/><font color="red">Diagnostics, Personnel</font><br/><font color="blue">Life Technologies</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Spectranetics Announces Interim Results from German Study Treating Patients with Peripheral In-Stent Restenosis]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034457</link>
			<pubDate>Thu, 02 Feb 2012 12:59:10 GMT</pubDate>
			<author><![CDATA[Spectranetics]]></author>
		 <description><![CDATA[Results Provide Basis for Landmark EXCITE ISR Trial Underway in United States

COLORADO SPRINGS, Colo.--(Healthcare Sales & Marketing Network)-- Spectranetics Corporation (Nasdaq:SPNC ) today announced six month interim results from the PATENT (Photo-Abl... <br/><font color="red">Devices, Interventional</font><br/><font color="blue">Spectranetics, PATENT study, peripheral in-stent restenosis, laser atherectomy</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Syneron Announces New Ground Breaking evolastin™ Procedure]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034456</link>
			<pubDate>Thu, 02 Feb 2012 12:55:22 GMT</pubDate>
			<author><![CDATA[Syneron Medical]]></author>
		 <description><![CDATA[One treatment procedure primed to propel facial aesthetic procedures forward with unique results and significant science

IRVINE, Calif., Feb. 2, 2012  (HSMN NewsFeed)  -- Syneron Medical Ltd. (NASDAQ: ELOS ), www.syneron.com, the global leader in medica... <br/><font color="red">Devices, Dermatology</font><br/><font color="blue">Syneron Medical, evolastin procedure</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC(R) for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034455</link>
			<pubDate>Thu, 02 Feb 2012 12:50:05 GMT</pubDate>
			<author><![CDATA[EUSA Pharma]]></author>
		 <description><![CDATA[LANGHORNE, Pennsylvania and OXFORD, England, February 2, 2012  (HSMN NewsFeed)  --EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclus... <br/><font color="red">Biopharmaceuticals, Oncology, Acquisitions</font><br/><font color="blue">EUSA Pharma, Alizé Pharma, ASPAREC , acute lymphoblastic leukemia</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Boston Scientific Announces First Implant and Market Launch of PROMUS Element(TM) Plus Stent System in Europe]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034454</link>
			<pubDate>Wed, 01 Feb 2012 18:52:52 GMT</pubDate>
			<author><![CDATA[Boston Scientific]]></author>
		 <description><![CDATA[Platinum chromium coronary stent with enhanced delivery system now available in Europe and other international countries

NATICK, Mass., Feb. 1, 2012  (HSMN NewsFeed)  -- Boston Scientific Corporation (NYSE: BSX ) announces first patient use and European... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Boston Scientific, PROMUS Element, Platinum Chromium, drug eluting stent</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[TearScience Achieves FDA Clearance for Second Generation LipiFlow(R) Thermal Pulsation System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034453</link>
			<pubDate>Wed, 01 Feb 2012 18:48:23 GMT</pubDate>
			<author><![CDATA[TearScience]]></author>
		 <description><![CDATA[New LipiFlow&reg; System Provides Enhanced Graphical User Interface and Ability to Perform Bilateral Treatment from a Single Device

MORRISVILLE, N.C.--(Healthcare Sales & Marketing Network)-- TearScience, Inc., a privately-held medical device company, t... <br/><font color="red">Devices, Ophthalmology, FDA</font><br/><font color="blue">TearScience, LipiFlow, Thermal Pulsation System, dry eye</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Dendreon Announces CEO and Chairman Succession Plan]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034452</link>
			<pubDate>Wed, 01 Feb 2012 13:02:41 GMT</pubDate>
			<author><![CDATA[Dendreon]]></author>
		 <description><![CDATA[John H. Johnson Elected President, Chief Executive Officer and Chairman-Elect, Dr. Mitchell H. Gold Elected Executive Chairman

Company to Hold Conference Call Today at 9:00 a.m. ET/6:00 a.m. PT


SEATTLE--(Healthcare Sales & Marketing Network)-- Febr... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Dendreon</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Toshiba’s Aquilion PRIME CT System Receives FDA Clearance]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034451</link>
			<pubDate>Wed, 01 Feb 2012 12:57:53 GMT</pubDate>
			<author><![CDATA[Toshiba America Medical Systems]]></author>
		 <description><![CDATA[New Addition to the Aquilion CT Product Family Offers Ultra-Low Dose and Ultra-Fast Workflow

TUSTIN, Calif.--(Healthcare Sales & Marketing Network)-- Toshiba America Medical Systems, Inc. announces the FDA clearance of the Aquilion™ PRIME CT system, the... <br/><font color="red">Devices, Radiology, FDA</font><br/><font color="blue">Toshiba America Medical Systems, Aquilion PRIME</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034450</link>
			<pubDate>Wed, 01 Feb 2012 12:54:38 GMT</pubDate>
			<author><![CDATA[Novartis]]></author>
		 <description><![CDATA[Phase III results showed 54% reduction in risk of recurrence and 55% reduction in risk of death after three years' adjuvant Gleevec in adults with KIT+ GIST(1)

Approval builds on vast experience with Gleevec, first approved 10 years ago for treatment of... <br/><font color="red">Biopharmaceuticals, Oncology, FDA</font><br/><font color="blue">Novartis, Gleevec, imatinib, gastrointestinal stromal tumor</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[CartiHeal Raises $5 Million in Financing to Support Agili-C For Single Stage Arthroscopic Cartilage Regeneration]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034449</link>
			<pubDate>Wed, 01 Feb 2012 12:48:46 GMT</pubDate>
			<author><![CDATA[CartiHeal]]></author>
		 <description><![CDATA[TEL AVIV, Israel--(Healthcare Sales & Marketing Network)-- CartiHeal (2009), Ltd, a privately held medical device company, focused on developing and bringing to market a proprietary, off-the-shelf, and cell-free cartilage regeneration technology, announced... <br/><font color="red">Devices, Orthopaedic, Venture Capital</font><br/><font color="blue">CartiHeal, Agili-C, Cartilage Regeneration</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[ISO 9001:2008 and ISO 13485:2003 Certifications for Vita Needle Company]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034448</link>
			<pubDate>Tue, 31 Jan 2012 20:32:16 GMT</pubDate>
			<author><![CDATA[Vita Needle]]></author>
		 <description><![CDATA[NEEDHAM, MA -- (Healthcare Sales & Marketing Network) --  Vita Needle Company recently celebrated dual certifications of its Quality Management Systems to the latest general ISO 9001:2008 and medical device manufacturing standards ISO 13485:2003.  In addit... <br/><font color="red">Devices, Regulatory</font><br/><font color="blue">Vita Needle</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cardinal Health Introduces Smart-Seal(TM) Surgical Mask]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034447</link>
			<pubDate>Tue, 31 Jan 2012 13:40:49 GMT</pubDate>
			<author><![CDATA[Cardinal Health]]></author>
		 <description><![CDATA[Fog-Reduction Technology, &quot;Cinch-And-Hug&quot; Single-Tie Design Provide Highest Level of Protection

DUBLIN, Ohio, Jan. 31, 2012  (HSMN NewsFeed)  -- Cardinal Health today announced the availability of its Smart-Seal™ surgical mask, designed to enh... <br/><font color="red">Devices, Surgery</font><br/><font color="blue">Cardinal Health, Smart-Seal, surgical mask</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[AngioDynamics to Acquire Navilyst Medical for $372 Million]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034446</link>
			<pubDate>Tue, 31 Jan 2012 13:36:30 GMT</pubDate>
			<author><![CDATA[AngioDynamics]]></author>
		 <description><![CDATA[AngioDynamics to host conference call today at 11:30 am ET

Increases Scale in Vascular Access and Peripheral Vascular Markets

Expands Product Portfolio and Adds Innovative Technologies

Strengthens Focus on Operational Excellence

Expected to be ... <br/><font color="red">Devices, Mergers & Acquisitions</font><br/><font color="blue">AngioDynamics, Navilyst Medical</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sorin Group Launches a New Complete Portfolio of Pacing, Defibrillation and Left Ventricular Leads]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034445</link>
			<pubDate>Tue, 31 Jan 2012 13:28:30 GMT</pubDate>
			<author><![CDATA[Sorin Group]]></author>
		 <description><![CDATA[New lead portfolio combined with Sorin Group’s innovative and intelligent devices provide full-featured systems for accurate management of arrhythmias and heart failure

MILAN--(Healthcare Sales & Marketing Network)-- Sorin Group, (MIL:SRN.MI ) (Reuters ... <br/><font color="red">Devices, Cardiology, Regulatory</font><br/><font color="blue">Sorin Group, pacing leads, TILDA pacing leads, VIGILA defibrillation leads</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[New Clinical Study Finds Use of Tissuemed's Sealant Film TissuePatchDural "Encouraging" in Prevention of CSF Leaks]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034444</link>
			<pubDate>Tue, 31 Jan 2012 13:23:00 GMT</pubDate>
			<author><![CDATA[Tissuemed]]></author>
		 <description><![CDATA[LEEDS, England, January 31, 2012  (HSMN NewsFeed)  -- UK surgical sealant film company Tissuemed Ltd. has announced the publication of a new clinical paper in World Neurosurgery relating to its self-adhesive dural sealant film products.

Authored by Dr P... <br/><font color="red">Devices, Neurosurgery</font><br/><font color="blue">Tissuemed, dural sealant film, TissuePatchDural</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Hospira Names Richard Davies Chief Commercial Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034443</link>
			<pubDate>Tue, 31 Jan 2012 00:03:15 GMT</pubDate>
			<author><![CDATA[Hospira]]></author>
		 <description><![CDATA[LAKE FOREST, Ill., Jan. 30, 2012  (HSMN NewsFeed)  -- Hospira, Inc. (NYSE: HSP ), the world's leading provider of injectable drugs and infusion technologies, today announced that Richard Davies has been named senior vice president and chief commercial offi... <br/><font color="red">Biopharmaceuticals, Drug Delivery, Personnel</font><br/><font color="blue">Hospira</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Physio-Control Completes Sale to Bain Capital]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034442</link>
			<pubDate>Tue, 31 Jan 2012 00:00:27 GMT</pubDate>
			<author><![CDATA[Physio-Control]]></author>
		 <description><![CDATA[Brian Webster Assumes Role of Chief Executive Officer

REDMOND, Wash. and BOSTON--(Healthcare Sales & Marketing Network)-- Physio-Control, the world’s leading provider of emergency medical response technology for use in the intervention and treatment of ... <br/><font color="red">Devices, Mergers & Acquisitions</font><br/><font color="blue">Physio-Control, Bain Capital</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[ImmunoGen, Inc. Announces Addition of Kristine Peterson and Dean Mitchell to Its Board of Directors]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034441</link>
			<pubDate>Mon, 30 Jan 2012 23:56:39 GMT</pubDate>
			<author><![CDATA[ImmunoGen]]></author>
		 <description><![CDATA[WALTHAM, Mass., Jan. 30, 2012 --(HSMN NewsFeed) -- ImmunoGen, Inc. (Nasdaq:IMGN ), a biotechnology company that develops targeted anticancer therapeutics using its antibody expertise, today announced the addition of Kristine Peterson and Dean Mitchell to t... <br/><font color="red">Biopharmaceuticals, Oncology, Personnel</font><br/><font color="blue">ImmunoGen</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Curis Announces FDA Approval of Erivedge(TM) (vismodegib) Capsule as First Treatment for Advanced Basal Cell Carcinoma]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034440</link>
			<pubDate>Mon, 30 Jan 2012 23:54:52 GMT</pubDate>
			<author><![CDATA[Curis]]></author>
		 <description><![CDATA[LEXINGTON, Mass., Jan. 30, 2012 --(HSMN NewsFeed) -- Curis, Inc. (Nasdaq:CRIS ), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that Erivedge(TM) (vismodegib) caps... <br/><font color="red">Biopharmaceuticals, Oncology, FDA</font><br/><font color="blue">Curis, Erivedge, vismodegib, basal cell carcinoma</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[CardioKinetix Receives Expanded CE Mark Approval for World's First Percutaneous Left Ventricular Partitioning Device, the Parachute(TM), for Treatment of Ischemic Heart Failure]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034439</link>
			<pubDate>Mon, 30 Jan 2012 23:50:10 GMT</pubDate>
			<author><![CDATA[CardioKinetix]]></author>
		 <description><![CDATA[MENLO PARK, CA--(Healthcare Sales & Marketing Network)- CardioKinetix Inc., a medical device company that has developed a novel transcatheter implant called the Parachute™ Ventricular Partitioning Device (Parachute™), announced today that it has received C... <br/><font color="red">Devices, Cardiology, Regulatory</font><br/><font color="blue">CardioKinetix, Parachute, Ventricular Partitioning Device, heart failure</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Baxter Announces FDA Approval of Expanded Indication for TISSEEL [Fibrin Sealant] for General Hemostasis in Surgery]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034438</link>
			<pubDate>Mon, 30 Jan 2012 15:23:31 GMT</pubDate>
			<author><![CDATA[Baxter International]]></author>
		 <description><![CDATA[DEERFIELD, Ill.--(Healthcare Sales & Marketing Network)-- Baxter International Inc. (NYSE:BAX ) announced today that the U.S. Food and Drug Administration (FDA) has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of ... <br/><font color="red">Devices, Surgery, FDA</font><br/><font color="blue">Baxter International, TISSEEL, Fibrin Sealant, hemostasis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cardinal Health and Cook Medical Announce Exclusive Agreement for Customizable Vascular Access Kitting Solution]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034437</link>
			<pubDate>Mon, 30 Jan 2012 13:35:43 GMT</pubDate>
			<author><![CDATA[Cook Medical]]></author>
		 <description><![CDATA[Cook Medical Central Venous Catheter Sets Now Available in Presource&reg; Procedural Kits

DUBLIN, Ohio--(Healthcare Sales & Marketing Network)-- Cardinal Health and Cook Medical today announced a two-year, exclusive agreement for the North American dist... <br/><font color="red">Devices, Distribution</font><br/><font color="blue">Cook Medical, Cardinal Health, CVC procedural kits</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Medtronic Announces FDA Approval of DF4 High-Voltage Connector System for Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Devices]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034436</link>
			<pubDate>Mon, 30 Jan 2012 13:30:51 GMT</pubDate>
			<author><![CDATA[Medtronic]]></author>
		 <description><![CDATA[New System Builds On Sprint Quattro&reg; Lead, Adding to the Company’s Portfolio of Innovative Technologies Proven to Treat Heart Rhythm Disorders

MINNEAPOLIS--(Healthcare Sales & Marketing Network)-- Medtronic, Inc. (NYSE:MDT ) today announced the U.S.... <br/><font color="red">Devices, Cardiology, FDA</font><br/><font color="blue">Medtronic, DF4 High-Voltage Connector System, CRT-D</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[ConforMIS Reaches Funding Milestone with $89 Million in Series E Financing]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034435</link>
			<pubDate>Mon, 30 Jan 2012 13:27:10 GMT</pubDate>
			<author><![CDATA[ConforMIS]]></author>
		 <description><![CDATA[One of the Largest Fundraises by a Private Healthcare Company in 2011 Will Be Used to Support Commercial Expansion, Manufacturing and R&D

BURLINGTON, Mass.--(Healthcare Sales & Marketing Network)-- Surpassing all previous fundraising rounds, privately-h... <br/><font color="red">Devices, Venture Capital</font><br/><font color="blue">ConforMIS</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Intellipharmaceutics Appoints Vice President Business Development]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034434</link>
			<pubDate>Mon, 30 Jan 2012 13:23:49 GMT</pubDate>
			<author><![CDATA[Intellipharmaceutics International]]></author>
		 <description><![CDATA[TORONTO, Jan. 30, 2012 --(HSMN NewsFeed) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI ) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral... <br/><font color="red">Biopharmaceuticals, Generics, Personnel</font><br/><font color="blue">Intellipharmaceutics International</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[EDAP Regains Ablatherm(R)-HIFU Distribution Rights in Canada and Caribbean]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034433</link>
			<pubDate>Mon, 30 Jan 2012 13:20:22 GMT</pubDate>
			<author><![CDATA[EDAP TMS]]></author>
		 <description><![CDATA[Leverages Growing U.S. Awareness and Demand for Minimally Invasive Prostate Cancer Treatment to Drive Off-Shore Market Potential

LYON, France, Jan. 30, 2012 --(HSMN NewsFeed) -- EDAP TMS SA (Nasdaq:EDAP ), a global leader in therapeutic ultrasound, anno... <br/><font color="red">Devices, Distribution</font><br/><font color="blue">EDAP TMS, Ablatherm, HIFU</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cynosure Receives FDA 510(k) Clearance for Cellulaze Cellulite Laser Workstation]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034432</link>
			<pubDate>Mon, 30 Jan 2012 13:16:47 GMT</pubDate>
			<author><![CDATA[Cynosure]]></author>
		 <description><![CDATA[World's First Minimally Invasive Aesthetic Device for Cellulite Reduction

WESTFORD, Mass., Jan. 30, 2012  (HSMN NewsFeed)  -- Cynosure, Inc. (NASDAQ: CYNO ) today announced that the U.S. Food and Drug Administration has cleared the Company's Cellulaze™ ... <br/><font color="red">Devices, Dermatology, FDA</font><br/><font color="blue">Cynosure, Cellulaze, cellulite</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034431</link>
			<pubDate>Mon, 30 Jan 2012 13:12:20 GMT</pubDate>
			<author><![CDATA[Biogen Idec]]></author>
		 <description><![CDATA[Addition of Seasoned HR Leader Supports Commitment to Driving Culture of Excellence

WESTON, Mass.--(Healthcare Sales & Marketing Network)-- Biogen Idec (NASDAQ:BIIB ) today announced that Kenneth DiPietro has been named Executive Vice President, Human R... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Biogen Idec</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034430</link>
			<pubDate>Mon, 30 Jan 2012 13:09:43 GMT</pubDate>
			<author><![CDATA[Cytori Therapeutics]]></author>
		 <description><![CDATA[SAN DIEGO, CA--(Healthcare Sales & Marketing Network)- Cytori Therapeutics (NASDAQ: CYTX ) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the ATHENA trial. ATHENA will investigate the use of the Celution&reg; Sys... <br/><font color="red">Regenerative Medicine, Cardiology</font><br/><font color="blue">Cytori Therapeutics, ATHENA trial, Celution System, chronic myocardial ischemia</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Valeant Pharmaceuticals Withdraws Offer for Acquisition of ISTA Pharmaceuticals Inc.]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034429</link>
			<pubDate>Mon, 30 Jan 2012 13:05:38 GMT</pubDate>
			<author><![CDATA[Valeant Pharmaceuticals International]]></author>
		 <description><![CDATA[MISSISSAUGA, Ontario, Jan. 30, 2012  (HSMN NewsFeed)  -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has withdrawn its offer to acquire ISTA Pharmaceuticals Inc. (Nasdaq: ISTA ) for $7.50 per share in cash. ... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">Valeant Pharmaceuticals International, ISTA Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Covidien Revascularization Device Approved for Interventional Management of Stroke Trial]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034428</link>
			<pubDate>Mon, 30 Jan 2012 13:02:25 GMT</pubDate>
			<author><![CDATA[Covidien]]></author>
		 <description><![CDATA[Physicians request Solitaire™ FR device for randomized, open-label multi-center study

MANSFIELD, Mass.--(Healthcare Sales & Marketing Network)-- Covidien (NYSE:COV ), a leading global provider of healthcare products, today announced that the Solitaire™ ... <br/><font color="red">Devices, Interventional, Neurology</font><br/><font color="blue">Covidien, Solitaire FR, Revascularization Device, stroke</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Wright Medical Group, Inc. Names Daniel Garen Senior Vice President and Chief Compliance Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034427</link>
			<pubDate>Mon, 30 Jan 2012 12:58:23 GMT</pubDate>
			<author><![CDATA[Wright Medical Group]]></author>
		 <description><![CDATA[ARLINGTON, Tenn.--(Healthcare Sales & Marketing Network)-- Wright Medical Group, Inc. (NASDAQ: WMGI ), a global orthopaedic medical device company and a leading provider of surgical solutions for the foot and ankle market, today announced that Daniel Garen... <br/><font color="red">Devices, Orthopaedic, Personnel</font><br/><font color="blue">Wright Medical Group</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Fourth German Hospital Selects IntraOp Medical Corporation’s Mobetron]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034426</link>
			<pubDate>Mon, 30 Jan 2012 12:44:48 GMT</pubDate>
			<author><![CDATA[IntraOp Medical]]></author>
		 <description><![CDATA[SUNNYVALE, Calif.--(Healthcare Sales & Marketing Network)-- IntraOp Medical Corporation (OTC: IOPD.PK ) today announced that Helios Berlin Buch became the fourth German hospital and the nineteenth European hospital to purchase a Mobetron for Intra-Operativ... <br/><font color="red">Devices, Oncology</font><br/><font color="blue">IntraOp Medical, Mobetron, IOERT</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cell Therapeutics Withdraws New Drug Application for Pixuvri™ and Plans to Resubmit in 2012]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034425</link>
			<pubDate>Mon, 30 Jan 2012 12:41:27 GMT</pubDate>
			<author><![CDATA[Cell Therapeutics]]></author>
		 <description><![CDATA[SEATTLE, Jan. 30, 2012  (HSMN NewsFeed)  -- Cell Therapeutics, Inc. (&quot;CTI&quot;) (Nasdaq and MTA: CTIC) announced today that it has voluntarily withdrawn its New Drug Application (&quot;NDA&quot;) for Pixuvri (pixantrone) for the treatment of relapsed... <br/><font color="red">Biopharmaceuticals, Oncology</font><br/><font color="blue">Cell Therapeutics, Pixuvri, pixantrone, non-Hodgkin's lymphoma</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera(R) Marketing Authorisation and Requests Further Information From the CHMP]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2034424</link>
			<pubDate>Mon, 30 Jan 2012 12:34:22 GMT</pubDate>
			<author><![CDATA[Amsterdam Molecular Therapeutics]]></author>
		 <description><![CDATA[AMSTERDAM, January 30, 2012  (HSMN NewsFeed)  --Amsterdam Molecular Therapeutics (Euronext: AMT ), a leader in the field of human gene therapy, was informed on Friday January 27, 2012 after business hours that the European Commission's Standing Committee o... <br/><font color="red">Biopharmaceuticals, Regulatory</font><br/><font color="blue">Amsterdam Molecular Therapeutics, Glybera, alipogene tiparvovec, LPLD</font>]]>
			</description>
	</item>
	</channel>
</rss>
